Várnai Máté, Kiss Zoltán, Gyulai Rolland, Oláh Judit, Holló Péter, Emri Gabriella, Csejtei András, Kenessey István, Benedek Angéla, Polányi Zoltán, Nagy-Erdei Zsófia, Dániel Andrea, Knollmajer Kata, Rokszin György, Fábián Ibolya, Barcza Zsófia, Polgár Csaba, Nagy Balázs, Liszkay Gabriella, Vokó Zoltán
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
MSD Pharma Hungary Ltd., Budapest, Hungary.
Front Oncol. 2021 Oct 19;11:745550. doi: 10.3389/fonc.2021.745550. eCollection 2021.
The incidence of melanoma has been increasing in the last decades. A retrospective Hungarian epidemiological study provided real-world data on incidence and mortality rates. There have been changing trends in incidence in Hungary in the last decade and mortality decreased, shifting mortality-to-incidence rate ratios (MIR). MIR is an indicator of cancer management quality.
Our aim is to show the changes of melanoma MIR in Hungary between 2011 and 2018 and to compare the real-world evidence-based results of our Hungarian nationwide retrospective study with other European countries.
MIR is calculated from the age-specific standardized incidence and mortality rates from our study. Annual MIR values are presented for the total population and for both sexes between 2011 and 2018, along with 95% confidence intervals. Comparison with European countries are shown for 2012 and 2018 based on the GLOBOCAN database and Eurostat health care expenditure per capita data.
MIR decreased by 0.035 during the study years. The decrease was same in both sexes (0.031). Male had higher MIRs in all study years. In both 2012 and 2018, Hungarian MIR in both sexes was lower than the European Union average (males: 0.192 vs. 0.212 and 0.148 vs. 0.174 respectively, women: 0.107 vs. 0.129 and 0.083 vs. 0.107 respectively).
Hungarian mortality-to-incidence ratio is the lowest in Central and Eastern Europe and is close to the level of Western and Northern European countries. The results are driven by the high number of new diagnosed melanoma cases.
在过去几十年中，黑色素瘤的发病率一直在上升。一项匈牙利回顾性流行病学研究提供了关于发病率和死亡率的真实世界数据。在过去十年中，匈牙利的发病率出现了变化趋势，死亡率下降，死亡率与发病率的比率（MIR）发生了变化。MIR是癌症管理质量的一个指标。
我们的目的是展示2011年至2018年匈牙利黑色素瘤MIR的变化，并将我们匈牙利全国性回顾性研究基于真实世界证据的结果与其他欧洲国家进行比较。
MIR是根据我们研究中按年龄标准化的发病率和死亡率计算得出 的。给出了2011年至2018年总人口和两性的年度MIR值以及95%置信区间 。基于GLOBOCAN数据库和欧盟统计局人均医疗保健支出数据，展示了2012年和2018年与欧洲国家的比较情况。
在研究期间MIR下降了0.035 两性下降幅度相同（0.031）。在所有研究年份中男性的MIR更高。在2012年和2018年，匈牙利两性的MIR均低于欧盟平均水平（男性分别为：0.192对0.212以及0.148对0.174；女性分别为：0.107对0.129以及0.083对0.107）。
匈牙利的死亡率与发病率之比在中欧和东欧是最低的，接近西欧和北欧国家的水平。结果是由新诊断黑色素瘤病例数量众多所驱动的。
